Doravirine / lamivudine / tenofovir disoproxil (new indication: HIV infection, patients aged 12 to < 18 years)

Subject:

• Active Substance: Doravirine / lamivudine / tenofovir disoxopril
• Name: Delstrigo®
• Therapeutic area: HIV infection
• Pharmaceutical company: MSD Sharp & Dohme GmbH

Time table:

• Start: 01.05.2022
• Final decision by G-BA: 20.10.2022

Final decision:

• No additional benefit proved